

# GLOBAL WHOLEHEALTH PARTNERS CORP

## **FORM 8-K** (Current report filing)

Filed 03/20/20 for the Period Ending 03/15/20

Address	2227 AVENIDA OLIVA SAN CLEMENTE, CA, 92673
Telephone	(714) 392-4112
CIK	0001598308
Symbol	GWHP
SIC Code	2835 - In Vitro and In Vivo Diagnostic Substances
Industry	Healthcare Facilities & Services
Sector	Healthcare
Fiscal Year	06/30

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2020

**GLOBAL WHOLEHEALTH PARTNERS CORPORATION**

(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction  
of incorporation)

000-56035  
(Commission File Number)

46-2316220  
(IRS Employer  
Identification No.)

2227 Avenida Oliva  
San Clemente, CA  
(Address of Principal Executive Offices)

92673  
(Zip Code)

Registrant's telephone number, including area code (714) 392-9752

N/A  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## **Section 8 - Other Events**

### **Item 8.01 Other Events.**

On March 15, 2020, the Registrant received an Acknowledgment Letter from the U.S. Food and Drug Administration that the Center for Devices and Radiological Health of the U.S Food and Drug Administration has received the Registrant's Emergency Use Approval for the Real Time PCR Test. The Registrant's submission has been assigned the unique document control number PEUA200084.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLOBAL WHOLEHEALTH PARTNERS CORPORATION**  
(Registrant)

Date: March 19, 2020

By: /s/ Charles Strongo  
Charles Strongo  
Chief Executive Officer